Abstract
Thyroid-associated ophthalmopathy (TAO) is the most common autoimmune inflammatory disease of the orbit. The CD40-CD40L pathway has been identified as a critical molecular mechanism contributing to the development and progression of TAO. In this study, we developed an RNA aptamer (CD40Apt) with specific binding affinity to CD40 as a potential inhibitor of this signaling pathway. CD40Apt was confirmed to specifically recognize mouse CD40-positive orbital fibroblasts with high affinity. In vitro, CD40Apt inhibited TGF-β-induced orbital fibroblast activation, reducing cell viability and the expression of fibrosis markers (α-SMA, Collagen I, Timp-1, and vimentin) while suppressing the phosphorylation of Erk, p38, JNK, and NF-κB. In a TAO mouse model, CD40Apt treatment improved eyelid broadening and ameliorated inflammatory infiltration and tissue hyperplasia without affecting body weight. These findings suggest that CD40Apt effectively suppresses orbital fibroblast activation and improves TAO symptoms by antagonizing the CD40 signaling pathway.
Introduction
Thyroid-associated ophthalmopathy (TAO) is a debilitating autoimmune condition characterized by orbital inflammation and tissue remodeling, often leading to proptosis (bulging eyes) and vision impairment. At the cellular level, orbital fibroblasts (OFs) are the primary drivers of this pathology. When activated via the CD40-CD40L signaling pathway, these cells overproduce inflammatory cytokines and extracellular matrix (ECM) components like collagen and hyaluronic acid. While monoclonal antibodies (mAbs) targeting these pathways exist, their high production costs and potential for immunogenicity limit their utility. This study investigates RNA aptamers—short, synthetic oligonucleotides that act as "chemical antibodies"—as a high-affinity, stable, and low-immunogenicity alternative for TAO therapy.
Aptamer Design and Stability
To overcome the rapid degradation of RNA in biological fluids, the researchers developed a chemically modified RNA aptamer. By incorporating 2-Fluoro-UTP and 2-Fluoro-CTP, the aptamer's resistance to nuclease degradation was significantly enhanced, allowing it to remain stable in mouse serum for at least seven days.
Binding Affinity and Specificity
A critical advantage of CD40Apt is its ability to recognize CD40 in its native state on the cell surface. Using flow cytometry and pull-down assays, the researchers demonstrated that the aptamer binds with high specificity and remarkable affinity to mouse orbital fibroblasts, achieving an equilibrium dissociation constant ($K_d$) of $35 \pm 7 \text{ nM}$.
In Vitro Inhibition of Fibroblast Activation
Using primary mouse orbital fibroblasts activated by TGF-β to mimic the disease state, the study found that CD40Apt administration significantly reduced cell viability and downregulated key fibrosis markers, including α-SMA, Collagen I, and Vimentin. Mechanistically, the aptamer suppressed a broad cascade of downstream signaling pathways, specifically inhibiting the phosphorylation of Erk, p38, JNK (MAPK pathways), and NF-κB.
In Vivo Therapeutic Efficacy in TAO Mice
The therapeutic potential of CD40Apt was further validated in a TAO mouse model established via TSHR-expressing adenovirus. Periorbital injections of CD40Apt led to visible clinical improvements:
- Symptom Reversal: Significant reduction in eyelid broadening and orbital tissue hyperplasia.
- Histopathological Improvement: Reduced inflammatory infiltration and collagen deposition in orbital muscle and adipose tissues.
- Safety Profile: No significant changes in body weight were observed, suggesting the localized treatment was well-tolerated.
Conclusion
CD40Apt represents a potent and specific antagonist of the CD40-CD40L signaling pathway. By binding to native CD40 proteins with high affinity, it successfully suppresses the activation of orbital fibroblasts and ameliorates the physical symptoms of TAO in mouse models. While further research is needed to develop human-specific sequences and optimize delivery methods, CD40Apt offers a promising new direction for the targeted treatment of autoimmune orbital diseases.
Summary updated